Zealand Pharma has struck a $100 million royalty deal with Royalty Pharma for its economic interests in rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera.
Under the agreement, Zealand receives $50 million upfront and another $50 million on the first anniversary of closing, while ceding most of its royalty and milestone rights on the drug, which is now developed by Takeda and Protagonist Therapeutics.
Separately, biotech startup Khartis Therapeutics has raised $50 million in a Series B round (bringing total funding to $95 million) to advance an oral, selective IGF-1R inhibitor for thyroid eye disease (TED), with plans to start its first clinical trial in the first quarter of 2027.
Sources:
Zealand Pharma enters into a USD 100 million royalty ...
Zealand sells milestone, royalty rights to rare blood cancer ...
Royalty Pharma Announces $205 Million Acquisition of ...
Zealand sells rights to Takeda's blood cancer drug for $100M
Royalty Pharma, Zealand Pharma Enter Rusfertide Funding Agreement
Pfizer vet debuts Khartis with sights set on thyroid eye disease
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate
Khartis Therapeutics Series B Financing | 13 comments - LinkedIn
OpenBio News | Biopharm & Life Sciences Intelligence
Khartis raises $50M Series B for oral immunology medicines - Axios
Clinical Trial and Drug Development News
Zealand cashes out rusfertide royalty for USD 100m ahead ...
Royalty Pharma And Zealand Pharma Enter Into Rusfertide Funding Agreement For $100 Million